Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice-Reference-Cited by-同舟云学术

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice

Published:2017-03-14 Issue:1 Volume:5 Page:
ISSN:2051-5960
Container-title:Acta Neuropathologica Communications
language:en
Short-container-title:acta neuropathol commun

Author:

Longo Francesco,Mercatelli Daniela,Novello Salvatore,Arcuri Ludovico,Brugnoli Alberto,Vincenzi Fabrizio,Russo Isabella,Berti Giulia,Mabrouk Omar S.,Kennedy Robert T.,Shimshek Derya R.,Varani Katia,Bubacco Luigi,Greggio Elisa,Morari Michele^ORCID

Funder

Michael J. Fox Foundation for Parkinson's Research

Fondazione Telethon

Italian Ministry of Health

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40478-017-0426-8.pdf

Reference95 articles.

1. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752. doi: 10.1074/jbc.M600933200

2. Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calo G, Bezard E, Morari M (2016) Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiol Dis 89:55–64. doi: 10.1016/j.nbd.2016.01.016

3. Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, Cao LP, Han H, Tapia L, Farrer MJ, Milnerwood AJ (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci 8:301. doi: 10.3389/fncel.2014.00301

4. Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ (2015) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 24:1336–1349. doi: 10.1093/hmg/ddu543

5. Bezard E (2003) Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. Lancet Neurol 2:393

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The AAV-α-Synuclein Model of Parkinson’s Disease: An Update;Journal of Parkinson's Disease;2024-09-03

2. Parkinson’s disease gene, Synaptojanin1, dysregulates the surface maintenance of the dopamine transporter;npj Parkinson's Disease;2024-08-08

3. Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson’s disease;Proceedings of the National Academy of Sciences;2024-08

4. Copper-mediated neurotoxicity and genetic vulnerability in the background of neurodegenerative diseases in C. elegans;Toxicological Sciences;2024-07-27

5. Leucine-Rich Repeat Kinase-2 Controls the Differentiation and Maturation of Oligodendrocytes in Mice and Zebrafish;Biomolecules;2024-07-19